thiazoles has been researched along with olaparib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, T; Lin, Y; Zhou, BP | 1 |
| Ledermann, JA | 1 |
| Aghajanian, C; Barry, WT; Birrer, M; Buss, MK; Cadoo, KA; Cantley, LC; Coleman, RL; Curtis, J; D'Andrea, AD; Eismann, J; Farooq, S; Kaufmann, SH; Kirschmeier, P; Kochupurakkal, B; Konstantinopoulos, PA; Liu, J; Luo, W; Matulonis, UA; Mayer, EL; Mills, GB; O'Cearbhaill, RE; Palakurthi, S; Shapiro, GI; Swisher, EM; Westin, SN; Whalen, C; Winer, E; Wulf, GM | 1 |
| Adalsteinsson, V; Batalini, F; Cantley, LC; D'Andrea, A; Eismann, J; Konstantinopoulos, PA; Matulonis, UA; Mayer, EL; Polak, M; Shapiro, GI; Swisher, EM; Tayob, N; Winer, EP; Wulf, GM; Xiong, N | 1 |
2 trial(s) available for thiazoles and olaparib
| Article | Year |
|---|---|
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Genome, Human; Humans; Maximum Tolerated Dose; Middle Aged; Mutation; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thiazoles; Treatment Outcome | 2019 |
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Female; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thiazoles; Triple Negative Breast Neoplasms | 2022 |
2 other study(ies) available for thiazoles and olaparib
| Article | Year |
|---|---|
Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner.
Topics: Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Methylation; Doxorubicin; Electrophoresis, Polyacrylamide Gel; Gene Expression Regulation; HEK293 Cells; Histone Demethylases; Humans; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; PTEN Phosphohydrolase; Real-Time Polymerase Chain Reaction; Snail Family Transcription Factors; Tetrazolium Salts; Thiazoles; Transcription Factors | 2014 |
Extending the scope of PARP inhibitors in ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thiazoles | 2019 |